RBC Capital Cuts PT on Concordia Int'l (CXRX) to $27 Following Q2 REsults

August 15, 2016 6:27 AM EDT
Get Alerts CXRX Hot Sheet
Price: $2.08 -4.59%

Rating Summary:
    0 Buy, 3 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade CXRX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

RBC Capital lowers its price target on Outperform-rated Concordia International (Nasdaq: CXRX) from $33 down to $27 following Q2 results last week.

The firm commented, Although we had recently revised our forecasts to reflect FX impact post-Brexit and weakness in the U.S. legacy business, our revisions were not significant enough and Concordia lowered its guidance beyond the Street's expectations. We believe the weakness Friday was overdone and would be buyers, as the shares now trade at a significant discount to peers (~30% '17E EV/EBITDA discount).

For an analyst ratings summary and ratings history on Concordia Healthcare click here. For more ratings news on Concordia Healthcare click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

RBC Capital

Add Your Comment